Acurx Pharmaceuticals, Inc. (ACXP)
NASDAQ: ACXP · Real-Time Price · USD
0.3790
-0.0009 (-0.24%)
May 14, 2025, 9:58 AM - Market open

Acurx Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Selling, General & Admin
7.438.78.537.3410.782.4
Upgrade
Research & Development
4.455.46.044.752.032.2
Upgrade
Operating Expenses
11.8714.114.5812.0912.814.6
Upgrade
Operating Income
-11.87-14.1-14.58-12.09-12.81-4.6
Upgrade
EBT Excluding Unusual Items
-11.87-14.1-14.58-12.09-12.81-4.6
Upgrade
Other Unusual Items
----0.07-
Upgrade
Pretax Income
-11.87-14.1-14.58-12.09-12.75-4.6
Upgrade
Net Income
-11.87-14.1-14.58-12.09-12.75-4.6
Upgrade
Net Income to Common
-11.87-14.1-14.58-12.09-12.75-4.6
Upgrade
Shares Outstanding (Basic)
1716131196
Upgrade
Shares Outstanding (Diluted)
1716131196
Upgrade
Shares Change (YoY)
26.96%27.56%17.15%26.72%37.88%30.29%
Upgrade
EPS (Basic)
-0.69-0.87-1.15-1.12-1.49-0.74
Upgrade
EPS (Diluted)
-0.69-0.87-1.15-1.12-1.49-0.74
Upgrade
EBIT
-11.87-14.1-14.58-12.09-12.81-4.6
Upgrade
Updated May 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q